Acrivon Therapeutics announced it will present late-breaking clinical data on its novel cancer drug ACR-2316, a WEE1/PKMYT1 inhibitor, at the 38th EORTC-NCI-AACR Symposium in November 2026. The presentations will include safety, dose optimization, and preliminary antitumor activity from a Phase 1 dose escalation study, highlighting promising results such as a confirmed complete response in lung cancer. Acrivon is also advancing other drug candidates using its proprietary AI-driven phosphoproteomics platform, aiming to develop precision medicines for cancer treatment. These updates underscore Acrivon's progress in clinical development and its innovative approach to drug discovery.
Acrivon Therapeutics' presentation of late-breaking clinical data on its cancer drug ACR-2316 provides context for health sector activity on Pluang. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 04:11 WIB: out of 150 priced US health stocks, 108 rose and 42 fell. Notably, AdaptHealth Corp (AHCO) surged 17.04% to USD 7.35 with a typical hold time of 21 days, while Acadia Healthcare (ACHC) gained 16.68% at USD 34.56 and Moderna (MRNA) increased 12.97% to USD 258.08, with hold times ranging from 9 to 58 days and a majority of sell orders across these names.
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
